Fennec Pharmaceuticals (FENC) Share-based Compensation (2010 - 2025)
Fennec Pharmaceuticals (FENC) posted Share-based Compensation of $6.9 million for Q4 2025, up 13644.0% on a QoQ basis from $50000.0 in Q3 2025, and up 282.72% year-over-year from $1.8 million in Q4 2024.
Fennec Pharmaceuticals (FENC) Share-based Compensation (2010 - 2025) Analysis & Trends
Fennec Pharmaceuticals' Share-based Compensation history runs 16 years deep, the most recent figure standing at $6.9 million for Q4 2025.
- Quarterly Share-based Compensation rose 282.72% year-over-year to $6.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.0 million (up 3896.02% YoY) and the FY2025 annual result came in at $7.0 million, up 40.1% from the prior year.
- Share-based Compensation was $6.9 million for Q4 2025 at Fennec Pharmaceuticals, up from $50000.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $6.9 million in Q4 2025 and bottomed at -$3.8 million in Q4 2024.
- A 5-year average of $667210.5 and a median of $798000.0 in 2025 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation soared 7165.71% — and 2024, when it slumped 538.86%.
- Fennec Pharmaceuticals' Share-based Compensation stood at -$2.6 million in 2021, then soared by 98.71% to -$33000.0 in 2022, then soared by 2696.97% to $857000.0 in 2023, then slumped by 538.86% to -$3.8 million in 2024, then soared by 282.72% to $6.9 million in 2025.
- Business Quant data shows FENC's Share-based Compensation at $6.9 million in Q4 2025, $50000.0 in Q3 2025, and -$687000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 3.20 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 9.26 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 87.30 Mn |
| 10 | Fennec Pharmaceuticals | 287.77 Mn | 250.98 Mn | 12.01 Mn | 6.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.87 Mn |
| Dec 31, 2025 | 6.87 Mn |
| Sep 30, 2025 | 50,000.00 |
| Sep 30, 2025 | 50,000.00 |
| Jun 30, 2025 | -687,000.00 |
| Jun 30, 2025 | -687,000.00 |
| Mar 31, 2025 | 798,000.00 |
| Mar 31, 2025 | 798,000.00 |
| Dec 31, 2024 | -3.76 Mn |
| Dec 31, 2024 | -3.76 Mn |
| Sep 30, 2024 | 1.82 Mn |
| Sep 30, 2024 | 1.82 Mn |
| Jun 30, 2024 | 2.10 Mn |
| Jun 30, 2024 | 2.10 Mn |
| Mar 31, 2024 | 19,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Dec 31, 2023 | 857,000.00 |
| Dec 31, 2023 | 857,000.00 |
| Sep 30, 2023 | 865,000.00 |
| Sep 30, 2023 | 865,000.00 |